Hengrui Pharma's stock price surged 5.31% during intraday trading on Thursday, following the release of its first-quarter financial results.
The pharmaceutical company reported robust performance for the first quarter of 2026, with revenue reaching RMB 8.141 billion, representing a 12.98% increase year-on-year. More significantly, net profit attributable to shareholders grew by 21.78% to RMB 2.282 billion compared to the same period last year.
The stronger-than-expected profit growth appears to have driven investor optimism, leading to the significant price appreciation during the trading session.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments